<DOC>
	<DOCNO>NCT02134834</DOCNO>
	<brief_summary>The objective study assess safety , tolerability pharmacokinetic profile OP0595 administer intravenously healthy male , Caucasian , adult subject single escalate dos .</brief_summary>
	<brief_title>A Phase I Study Assess Safety , Tolerability Pharmacokinetics OP0595</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Caucasian male age 18 45 year ( inclusive ) Screening A Body Mass Index ( BMI ) 18.0 30.0 kg/mÂ² ( inclusive ) Screening Good general health determine Investigator base medical history , physical examination , vital sign , 12lead ECG clinical laboratory test Negative urine test drug abuse breath test alcohol Screening Day 1 Receipt investigational agent drug within four month Screening A history current evidence allergic symptom bronchial asthma , druginduced rash urticaria Hypersensitivity and/or allergy drug Concurrent history clinically significant cardiovascular , hepatic , renal , endocrine , gastrointestinal , respiratory , psychiatric , neurologic and/or hematological disorder A history chronic recurrent infection current active infection A recent history surgery within three month prior Screening , determine Investigator clinically relevant A history presence malignancy Donation blood ( loss blood ) great 400 ml within three month Screening A history smoking time within one year Screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>